隐藏的澳大利亚皮肤癌流行病--高危皮肤鳞状细胞癌:叙述性综述。

IF 3.6 3区 医学 Q1 PATHOLOGY
Andrew Dettrick , Neil Foden , David Hogan , Mary Azer , John Blazak , Daisy Atwell , Nicole Buddle , Myo Min , Ryan Livingston , Leith Banney , Rebecca Donkin
{"title":"隐藏的澳大利亚皮肤癌流行病--高危皮肤鳞状细胞癌:叙述性综述。","authors":"Andrew Dettrick ,&nbsp;Neil Foden ,&nbsp;David Hogan ,&nbsp;Mary Azer ,&nbsp;John Blazak ,&nbsp;Daisy Atwell ,&nbsp;Nicole Buddle ,&nbsp;Myo Min ,&nbsp;Ryan Livingston ,&nbsp;Leith Banney ,&nbsp;Rebecca Donkin","doi":"10.1016/j.pathol.2024.05.002","DOIUrl":null,"url":null,"abstract":"<div><p>Deaths from non-melanoma skin cancers (NMSCs) have almost doubled in Australia in recent years. Cutaneous squamous cell carcinoma (cSCC) constitutes approximately 20% of NMSCs, but is responsible for most of the deaths. Most skin cancers are easy to diagnose and treat and therefore cSCC are often trivialised; however, there is a high-risk subgroup of cSCC (HRcSCC) that is associated with a high risk of metastasis and death. The definition of early HRcSCC and our ability to identify them is evolving. Many significant prognostic factors have been identified, but a universally accepted prognostic index does not exist. Guidelines for workup, treatment, and follow-up leave many important decisions open to broad interpretation by the treating physician or multidisciplinary team. Some of the treatments used for metastatic cSCC are not supported by robust evidence and the prognosis of metastatic cSCC is guarded. In this review, we highlight the rapid rise in NMSC deaths and discuss some of the deficiencies in our knowledge of how to define, diagnose, stage, and manage HRcSCC.</p></div>","PeriodicalId":19915,"journal":{"name":"Pathology","volume":"56 5","pages":"Pages 619-632"},"PeriodicalIF":3.6000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0031302524001338/pdfft?md5=7918139e5df902886fd5694e80438c23&pid=1-s2.0-S0031302524001338-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The hidden Australian skin cancer epidemic, high-risk cutaneous squamous cell carcinoma: a narrative review\",\"authors\":\"Andrew Dettrick ,&nbsp;Neil Foden ,&nbsp;David Hogan ,&nbsp;Mary Azer ,&nbsp;John Blazak ,&nbsp;Daisy Atwell ,&nbsp;Nicole Buddle ,&nbsp;Myo Min ,&nbsp;Ryan Livingston ,&nbsp;Leith Banney ,&nbsp;Rebecca Donkin\",\"doi\":\"10.1016/j.pathol.2024.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Deaths from non-melanoma skin cancers (NMSCs) have almost doubled in Australia in recent years. Cutaneous squamous cell carcinoma (cSCC) constitutes approximately 20% of NMSCs, but is responsible for most of the deaths. Most skin cancers are easy to diagnose and treat and therefore cSCC are often trivialised; however, there is a high-risk subgroup of cSCC (HRcSCC) that is associated with a high risk of metastasis and death. The definition of early HRcSCC and our ability to identify them is evolving. Many significant prognostic factors have been identified, but a universally accepted prognostic index does not exist. Guidelines for workup, treatment, and follow-up leave many important decisions open to broad interpretation by the treating physician or multidisciplinary team. Some of the treatments used for metastatic cSCC are not supported by robust evidence and the prognosis of metastatic cSCC is guarded. In this review, we highlight the rapid rise in NMSC deaths and discuss some of the deficiencies in our knowledge of how to define, diagnose, stage, and manage HRcSCC.</p></div>\",\"PeriodicalId\":19915,\"journal\":{\"name\":\"Pathology\",\"volume\":\"56 5\",\"pages\":\"Pages 619-632\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0031302524001338/pdfft?md5=7918139e5df902886fd5694e80438c23&pid=1-s2.0-S0031302524001338-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0031302524001338\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0031302524001338","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

近年来,澳大利亚死于非黑色素瘤皮肤癌(NMSCs)的人数几乎翻了一番。皮肤鳞状细胞癌(cSCC)约占非黑素瘤皮肤癌的20%,但却是造成大多数人死亡的原因。大多数皮肤癌都很容易诊断和治疗,因此 cSCC 常常被轻视;然而,cSCC 中有一个高风险亚组(HRcSCC)与高转移和死亡风险相关。早期 HRcSCC 的定义以及我们识别它们的能力正在不断发展。目前已经确定了许多重要的预后因素,但还没有一个普遍接受的预后指数。关于检查、治疗和随访的指南使得许多重要的决定可以由主治医生或多学科团队做出广泛的解释。用于转移性 cSCC 的一些治疗方法没有可靠的证据支持,而且转移性 cSCC 的预后令人担忧。在这篇综述中,我们强调了NMSC死亡人数的迅速上升,并讨论了我们在如何定义、诊断、分期和管理HRcSCC方面存在的一些知识缺陷。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The hidden Australian skin cancer epidemic, high-risk cutaneous squamous cell carcinoma: a narrative review

Deaths from non-melanoma skin cancers (NMSCs) have almost doubled in Australia in recent years. Cutaneous squamous cell carcinoma (cSCC) constitutes approximately 20% of NMSCs, but is responsible for most of the deaths. Most skin cancers are easy to diagnose and treat and therefore cSCC are often trivialised; however, there is a high-risk subgroup of cSCC (HRcSCC) that is associated with a high risk of metastasis and death. The definition of early HRcSCC and our ability to identify them is evolving. Many significant prognostic factors have been identified, but a universally accepted prognostic index does not exist. Guidelines for workup, treatment, and follow-up leave many important decisions open to broad interpretation by the treating physician or multidisciplinary team. Some of the treatments used for metastatic cSCC are not supported by robust evidence and the prognosis of metastatic cSCC is guarded. In this review, we highlight the rapid rise in NMSC deaths and discuss some of the deficiencies in our knowledge of how to define, diagnose, stage, and manage HRcSCC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pathology
Pathology 医学-病理学
CiteScore
6.50
自引率
2.20%
发文量
459
审稿时长
54 days
期刊介绍: Published by Elsevier from 2016 Pathology is the official journal of the Royal College of Pathologists of Australasia (RCPA). It is committed to publishing peer-reviewed, original articles related to the science of pathology in its broadest sense, including anatomical pathology, chemical pathology and biochemistry, cytopathology, experimental pathology, forensic pathology and morbid anatomy, genetics, haematology, immunology and immunopathology, microbiology and molecular pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信